Cost-utility analysis of switching to gemcitabine maintenance therapy for malignant mesothelioma patients after first-line chemotherapy

YOU Jun; XIN Wenxiu; HE Chaoneng; FANG Qilu

doi:10.6039/j.issn.1001-0408.2025.07.13

您当前的位置：

首页 >

文章列表页 >

Cost-utility analysis of switching to gemcitabine maintenance therapy for malignant mesothelioma patients after first-line chemotherapy

更新时间：2025-04-09

- Cost-utility analysis of switching to gemcitabine maintenance therapy for malignant mesothelioma patients after first-line chemotherapy
- ZHONGGUO YAOFANG Vol. 36, Issue 7, Pages: 843-847(2025)
- 作者机构：
  
  浙江省肿瘤医院药剂科，杭州　310022
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.07.13
  CLC： R956;R734.3
- Received：11 August 2024，
  
  Revised：20 March 2025，
  
  Accepted：2025-03-21，
  
  Published：15 April 2025
- 稿件说明：
移动端阅览
游隽,辛文秀,何超能等.恶性间皮瘤患者一线化疗后转换吉西他滨维持治疗的成本-效用分析 ^Δ[J].中国药房,2025,36(07):843-847.

YOU Jun,XIN Wenxiu,HE Chaoneng,et al.Cost-utility analysis of switching to gemcitabine maintenance therapy for malignant mesothelioma patients after first-line chemotherapy[J].ZHONGGUO YAOFANG,2025,36(07):843-847.
游隽,辛文秀,何超能等.恶性间皮瘤患者一线化疗后转换吉西他滨维持治疗的成本-效用分析 ^Δ[J].中国药房,2025,36(07):843-847. DOI： 10.6039/j.issn.1001-0408.2025.07.13.

YOU Jun,XIN Wenxiu,HE Chaoneng,et al.Cost-utility analysis of switching to gemcitabine maintenance therapy for malignant mesothelioma patients after first-line chemotherapy[J].ZHONGGUO YAOFANG,2025,36(07):843-847. DOI： 10.6039/j.issn.1001-0408.2025.07.13.

摘要

目的

从中国卫生体系的角度出发，评估不可切除的恶性间皮瘤患者经一线化疗后，转换吉西他滨维持治疗的经济性。

方法

根据NVALT19试验数据构建分区生存模型，循环周期为21 d，研究时限为10年，贴现率为5%。模型的主要输出参数包括总成本、质量调整生命年（QALY）、增量成本和增量成本-效果比（ICER）等。采用成本-效用分析法评价不可切除的恶性间皮瘤患者经一线化疗后转换吉西他滨维持治疗（吉西他滨组）方案相对于采用最佳支持治疗（支持治疗组）方案的经济性，并进行敏感性分析。

结果

与支持治疗组方案相比，吉西他滨组方案的ICER为54 860.50元/QALY，远小于以3倍2023年我国人均国内生产总值作为的意愿支付阈值（268 077元/QALY），说明吉西他滨组方案具有经济性。单因素敏感性分析结果显示，临终关怀成本和吉西他滨组不良事件处理成本对ICER的影响较大；概率敏感性分析结果表明，当意愿支付阈值大于270 000元/QALY时，吉西他滨组方案具有经济性的概率为100%。

结论

从中国卫生体系的角度出发，不可切除的恶性间皮瘤在一线化疗后转换吉西他滨维持治疗的方案具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-utility of switching to gemcitabine maintenance therapy for patients with unresectable malignant mesothelioma after first-line chemotherapy from the perspective of China’s healthcare system.

METHODS

A partitioned survival model was constructed based on data from the NVALT19 trial， with a cycle length of 21 days， a time horizon of 10 years， and a discount rate of 5%. Key model outputs included total costs， quality-adjusted life year （QALY）， incremental costs， and incremental cost-effectiveness ratio （ICER）， etc. Cost-utility analysis was conducted to evaluate the cost-effectiveness of gemcitabine maintenance therapy （gemcitabine group） plan versus best supportive care （supportive care group） plan for the patients with unresectable malignant mesothelioma after first-line chemotherapy. Sensitivity analyses were performed.

RESULTS

Compared with the supportive care group plan， the gemcitabine group plan had an ICER of 54 860.50 yuan/QALY， which was significantly lower than the willingness-to-pay （WTP） threshold （3 times China’s 2023 per capita gross domestic product， 268 077 yuan/QALY）， indicating that gemcitabine group plan was cost-effective. One-way sensitivity analysis revealed that end-of-life care costs and adverse event management costs in the gemcitabine group had the greatest impact on ICER. Probabilistic sensitivity analysis showed gemcitabine group plan was 100% cost-effective when WTP exceeded 270 000 yuan/QALY.

CONCLUSIONS

From the perspective of China’s healthcare system， switching to gemcitabine maintenance therapy after first-line chemotherapy is cost-effective for unresectable malignant mesothelioma.

关键词

Keywords

references

GREENBAUM A ， ALEXANDER H R . Peritoneal mesothelioma [J ] . Transl Lung Cancer Res ， 2020 ， 9 （ Suppl. 1 ）： S120 - S132 .

NAPOLITANO A ， CARBONE M . Malignant mesothelioma：time to translate? [J ] . Trends Cancer ， 2016 ， 2 （ 9 ）： 467 - 474 .

KURIBAYASHI K ， DOI H ， KIJIMA T . Types of surgery post-neoadjuvant chemotherapy for pleural mesothelioma [J ] . Expert Rev Respir Med ， 2019 ， 13 （ 12 ）： 1189 - 1194 .

VISCARDI G ， DI LIELLO R ， MORGILLO F . How I treat malignant pleural mesothelioma [J ] . ESMO Open ， 2020 ， 4 （ Suppl. 2 ）： e000669 .

VOGELZANG N J ， RUSTHOVEN J J ， SYMANOWSKI J ， et al . Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [J ] . J Clin Oncol ， 2003 ， 21 （ 14 ）： 2636 - 2644 .

ZALCMAN G ， MAZIERES J ， MARGERY J ， et al . Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study （MAPS）：a randomized，controlled，open-label，phase 3 trial [J ] . Lancet ， 2016 ， 387 （ 10026 ）： 1405 - 1414 .

DE GOOIJER C J ， VAN DER NOORT V ， STIGT J A ， et al . Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma （NVALT19）：an investigator-initiated，randomized，open-label，phase 2 trial [J ] . Lancet Respir Med ， 2021 ， 9 （ 6 ）： 585 - 592 .

LENCIONI R ， LLOVET J M . Modified RECIST （mRECIST） assessment for hepatocellular carcinoma [J ] . Semin Liver Dis ， 2010 ， 30 （ 1 ）： 52 - 60 .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ：4- 5 ， 19 ， 27 - 28 .

国家统计局 . 中华人民共和国2023年国民经济和社会发展统计公报 [EB/OL ] .（ 2024-02-29 ）[ 2024-07-01 ] . https：//www.stats.gov.cn/sj/zxfb/202402/t20240228_1947915.html https://www.stats.gov.cn/sj/zxfb/202402/t20240228_1947915.html .

LIU S X ， DOU L ， LI S P . Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China [J ] . Front Pharmacol ， 2023 ， 14 ： 1055727 .

浙江省医疗保障局浙江省医疗保障局关于公布部分调整完善医疗服务价格项目的通知 [EB/OL ] . （ 2022-11-28 ）[ 2024-06-29 ] . http：//ybj.zj.gov.cn/art/2022/11/28/art_1229113757_2448689.html http://ybj.zj.gov.cn/art/2022/11/28/art_1229113757_2448689.html .

MURRAY C J ， EVANS D B ， ACHARYA A ， et al . Deve- lopment of WHO guidelines on generalized cost-effectiveness analysis [J ] . Health Econ ， 2000 ， 9 （ 3 ）： 235 - 251 .

ZHAN M ， ZHENG H R ， XU T ， et al . Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial [J ] . Lung Cancer ， 2017 ， 110 ： 1 - 6 .

WU B ， YAO Y ， ZHANG K ， et al . RAS testing and cetu- ximab treatment for metastatic colorectal cancer：a cost-effectiveness analysis in a setting with limited health resources [J ] . Oncotarget ， 2017 ， 8 （ 41 ）： 71164 - 71172 .

SHU Y M ， LIU Y X ， HE X C ， et al . Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in China [J ] . Front Pharmacol ， 2022 ， 13 ： 818579 .

CORDONY A ， LE REUN C ， SMALA A ， et al . Cost-effectiveness of pemetrexed plus cisplatin：malignant pleural mesothelioma treatment in UK clinical practice [J ] . Value Health ， 2008 ， 11 （ 1 ）： 4 - 12 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-utility analysis of benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer

Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer

Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced， recurrent or metastatic esophageal squamous cell carcinoma

Related Author

FENG Bing

GAO Ning

GAO Shengnan

ZHANG Yuxi

ZHANG Ranran

LIU Guoqiang

QI Ran

NIE Xuyang

Related Institution

Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital

Hebei Provincial Association for Comprehensive Evaluation of Medicines and Health Technologies

Dept. of Clinical Pharmacy， the Third Hospital of Hebei Medical University

Dept. of Clinical Pharmacology Research， the Fourth Hospital of Hebei Medical University

First College of Clinical Medicine， Henan University of Chinese Medicine

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰